INOLYSIS Wins the “Rising Star” Award at Startup Greece Week 2025! INOLYSIS participated in Startup Greece Week 2025 , organized by the Athens Chamber of Commerce and Industry (ACCI) and the Athens Startup Incubator (THEA). The event, held on October 16th, 2025, brought together startups, investors, and industry leaders for a series of workshops and pitching sessions fostering innovation and entrepreneurship. Three investment funds selected INOLYSIS to deliver dedicated pitch

INOLYSIS Engages with Biotech Leaders at Bio3 Startup Pitching We are excited to share that INOLYSIS participated in Session 21a – Startup Pitching at Bio3: BioInnovation Greece, held at Innovathens on September 9th. This session brought together pioneering startups, biotech leaders, and healthtech innovators from Greece and abroad to present their cutting-edge solutions. Our Chief Medicinal Chemist, Alexios Matralis, represented INOLYSIS, showcasing our commitment to advanci

INOLYSIS at TIF 2025: Highlights from the Thessaloniki Innovation Fair We are proud to share that INOLYSIS participated in TIF 2025 , the Thessaloniki Technology, Research & Innovation Fair, presenting our breakthroughs in fibrosis therapy. Alexandra Boutla delivered a presentation showcasing our advances in fibrosis research and the innovative approaches we are developing to transform cutting-edge science into life-changing treatments. TIF provided the perfect platform to p

INOLYSIS Joins THEA to Accelerate Therapeutic Innovation We are thrilled to announce that INOLYSIS has officially joined THEA , the Athens-based startup ecosystem dedicated to supporting early-stage companies in the biotech and life sciences sector. By signing a Collaboration Agreement with THEA , INOLYSIS gains access to a dynamic environment designed to fuel innovation and growth. Joining THEA means that INOLYSIS now benefits from: Tailored Services : Specialized support t

INOLYSIS Receives ERC PoC Funding to Advance Innovative IBD Therapy INOLYSIS has been awarded an ERC Proof of Concept Grant to support the development of a novel oral therapy targeting fibroblast-driven inflammation and fibrosis in IBD . This prestigious grant from the European Research Council (ERC) will accelerate the development of INOLYSIS’s lead compound VM-313, an innovative oral therapy that uniquely targets fibroblasts—the key cellular drivers of inflammation and fib